Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454 Alone and in Combination With Ipilimumab and Nivolumab

Next Previous
Trial Profile

A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454 Alone and in Combination With Ipilimumab and Nivolumab

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TP-1454 (Primary) ; Ipilimumab; Nivolumab
  • Indications Anal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Sumitomo Pharma America; Sumitomo Pharma Oncology; Tolero Pharmaceuticals

Most Recent Events

  • 01 May 2025 Status changed from active, no longer recruiting to completed.
  • 10 Dec 2024 Planned End Date changed from 31 Oct 2024 to 31 May 2025.
  • 10 Dec 2024 Planned primary completion date changed from 31 Oct 2024 to 31 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top